These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28932273)

  • 1. The global impact of IBS: time to think about IBS-specific models of care?
    Corsetti M; Whorwell P
    Therap Adv Gastroenterol; 2017 Sep; 10(9):727-736. PubMed ID: 28932273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome.
    Lackner JM; Ma CX; Keefer L; Brenner DM; Gudleski GD; Satchidanand N; Firth R; Sitrin MD; Katz L; Krasner SS; Ballou SK; Naliboff BD; Mayer EA
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1147-57. PubMed ID: 23524278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in irritable bowel syndrome: Exploring mediating factors through structural equation modelling.
    Trindade IA; Melchior C; Törnblom H; Simrén M
    J Psychosom Res; 2022 Aug; 159():110809. PubMed ID: 35649318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.
    Singh P; Staller K; Barshop K; Dai E; Newman J; Yoon S; Castel S; Kuo B
    World J Gastroenterol; 2015 Jul; 21(26):8103-9. PubMed ID: 26185382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in pharmacological treatment of irritable bowel syndrome.
    Lazaraki G; Chatzimavroudis G; Katsinelos P
    World J Gastroenterol; 2014 Jul; 20(27):8867-85. PubMed ID: 25083060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irritable Bowel Syndrome: Treating the Gut and Brain/Mind at the Same Time.
    Jayasinghe M; Damianos JA; Prathiraja O; Oorloff MD; Nagalmulla K GM; Nadella A; Caldera D; Mohtashim A
    Cureus; 2023 Aug; 15(8):e43404. PubMed ID: 37706135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted pharmacotherapy of irritable bowel syndrome.
    Arokiadoss A; Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):214-221. PubMed ID: 33481423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fear of GI symptoms has an important impact on quality of life in patients with moderate-to-severe IBS.
    Lackner JM; Gudleski GD; Ma CX; Dewanwala A; Naliboff B;
    Am J Gastroenterol; 2014 Nov; 109(11):1815-23. PubMed ID: 25223577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of abuse and mood on bowel symptoms and health-related quality of life in irritable bowel syndrome (IBS).
    Kanuri N; Cassell B; Bruce SE; White KS; Gott BM; Gyawali CP; Sayuk GS
    Neurogastroenterol Motil; 2016 Oct; 28(10):1508-17. PubMed ID: 27151081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comorbidity and use of health-care services among irritable bowel syndrome sufferers.
    Hillilä MT; Siivola MT; Färkkilä MA
    Scand J Gastroenterol; 2007 Jul; 42(7):799-806. PubMed ID: 17558902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.
    Nellesen D; Yee K; Chawla A; Lewis BE; Carson RT
    J Manag Care Pharm; 2013; 19(9):755-64. PubMed ID: 24156644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain.
    Mearin F; Caballero AM; Serra J; Brotons C; Tantiñà A; Fort E; Martínez-Cerezo FJ; Perelló A; Sánchez-Antolín G; Rey E; Angós Musgo R; Berdier R; Gómez-Rodríguez B; Clavé P; García-Alonso M; Torán-Monserrat P; Tack J
    Gastroenterol Hepatol; 2019 Mar; 42(3):141-149. PubMed ID: 30612850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychosocial impact of irritable bowel syndrome: A brief review.
    Ballou S; Bedell A; Keefer L
    World J Gastrointest Pathophysiol; 2015 Nov; 6(4):120-3. PubMed ID: 26600969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. I am doing the best that I can!: Living with inflammatory bowel disease and/or irritable bowel syndrome (part II).
    Fletcher PC; Schneider MA; Van Ravenswaay V; Leon Z
    Clin Nurse Spec; 2008; 22(6):278-85. PubMed ID: 18955845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of disturbed sleep on gastrointestinal and somatic pain symptoms in irritable bowel syndrome.
    Patel A; Hasak S; Cassell B; Ciorba MA; Vivio EE; Kumar M; Gyawali CP; Sayuk GS
    Aliment Pharmacol Ther; 2016 Aug; 44(3):246-58. PubMed ID: 27240555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The burden of illness of irritable bowel syndrome: current challenges and hope for the future.
    Hulisz D
    J Manag Care Pharm; 2004; 10(4):299-309. PubMed ID: 15298528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.
    Everitt H; Landau S; Little P; Bishop FL; O'Reilly G; Sibelli A; Holland R; Hughes S; Windgassen S; McCrone P; Goldsmith K; Coleman N; Logan R; Chalder T; Moss-Morris R
    Health Technol Assess; 2019 Apr; 23(17):1-154. PubMed ID: 31042143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.